Peptinov was founded in 2010 and is located in the campus of Cochin Hospital in Paris. Peptinov is a privately held biotechnology company focused on the development of peptide-based immunotherapies targeting self-proteins, for the treatment of chronic inflammatory diseases and cancers.
Peptinov’s products are based on its innovative technology, which stems from the research of Prof. Zagury’s team in Cnam University (Paris).
Peptinov’s PPV-06 lead immunotherapy targets IL-6, a central pro-inflammatory cytokine whose overproduction is involved in the pathogenesis of several inflammatory diseases and also in several cancers.
Peptinov’s ambition and mission is to provide innovative and adequate therapies to patients affected by inflammatory diseases and cancers. With a team of experienced scientists as well as the support of our partners and investors, Peptinov is committed to improve the treatments available for these patients and their quality of life.